<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gsk3b</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GSK3B</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glycogen Synthase Kinase 3 Beta</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2932</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P49841</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>605004</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>420 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~47 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (highest), liver, muscle, kidney</td>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Direct GSK3β inhibitor</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>Selective GSK3β inhibitor</td>
</tr>
<tr>
<td class="label">SB 216763</td>
<td>ATP-competitive inhibitor</td>
</tr>
<tr>
<td class="label">AZD1080</td>
<td>Brain-penetrant inhibitor</td>
</tr>
<tr>
<td class="label">CHIR99021</td>
<td>GSK3α/β inhibitor</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Site(s)</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Ser199, 202, 205, 396, 404</td>
</tr>
<tr>
<td class="label">β-catenin</td
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">gsk3b</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GSK3B</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Glycogen Synthase Kinase 3 Beta</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>3q13.33</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2932</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P49841</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>605004</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>420 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~47 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (highest), liver, muscle, kidney</td>
</tr>
<tr>
<td class="label">Drug/Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>Direct GSK3β inhibitor</td>
</tr>
<tr>
<td class="label">Tideglusib</td>
<td>Selective GSK3β inhibitor</td>
</tr>
<tr>
<td class="label">SB 216763</td>
<td>ATP-competitive inhibitor</td>
</tr>
<tr>
<td class="label">AZD1080</td>
<td>Brain-penetrant inhibitor</td>
</tr>
<tr>
<td class="label">CHIR99021</td>
<td>GSK3α/β inhibitor</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Site(s)</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Ser199, 202, 205, 396, 404</td>
</tr>
<tr>
<td class="label">β-catenin</td>
<td>Ser33/37/45</td>
</tr>
<tr>
<td class="label">Glycogen synthase</td>
<td>Ser21</td>
</tr>
<tr>
<td class="label">CREB</td>
<td>Ser133</td>
</tr>
<tr>
<td class="label">NF-κB p65</td>
<td>Ser276</td>
</tr>
<tr>
<td class="label">α-synuclein</td>
<td>Ser129</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">CANCER</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">346 edges</a></td>
</tr>
</table>
GSK3B (Glycogen Synthase Kinase 3 Beta) is a serine/threonine-protein kinase that plays a central role in energy metabolism, neuronal cell development, and body pattern formation. It is one of the most actively studied kinases in neurodegeneration research due to its pivotal role in [tau](/proteins/tau) hyperphosphorylation. GSK3β is a proline-directed kinase that phosphorylates substrates at serine or threonine residues followed by proline (S/T-P motifs), making it unique among protein kinases. The human GSK3B gene encodes a 420-amino acid protein with a molecular weight of approximately 47 kDa, expressed ubiquitously with particularly high levels in the brain[@hooper2008].
GSK3β exists as two isoforms: GSK3α (51 kDa) and GSK3β (47 kDa), encoded by separate genes. While both isoforms share significant sequence homology and can phosphorylate many of the same substrates, they have distinct functions in certain cellular contexts. GSK3β is the predominant isoform in the nervous system and has been more extensively studied in the context of neurodegeneration. The kinase is localized in various cellular compartments including the cytoplasm, nucleus, mitochondria, and synapses, where it participates in diverse signaling pathways.
The central position of GSK3β as a signaling hub makes it a critical node in cellular decision-making between survival and death. Under resting conditions, GSK3β activity is suppressed by various mechanisms including phosphorylation at Ser9 (by Akt, PKA, and other kinases). When this inhibition is removed, GSK3β becomes active and can phosphorylate numerous substrates, leading to wide-ranging cellular effects that are particularly relevant to neurodegeneration.
The GSK3B gene encodes a protein kinase that is ubiquitously expressed but particularly abundant in the brain. GSK3β is a key downstream target of the PI3K/Akt signaling pathway and is inhibited by phosphorylation at Ser9. Dysregulation of GSK3β activity contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[@kremer2011]. The kinase participates in over 100 known substrate interactions, affecting processes ranging from glycogen metabolism and gene expression to synaptic plasticity and cell survival.
GSK3β is unique among protein kinases in its ability to recognize and phosphorylate substrates that are already phosphorylated at a priming phosphorylation site. This "primed phosphorylation" mechanism allows for precise temporal control of substrate activity, where GSK3β can amplify or modulate signaling cascades initiated by other kinases. This property makes GSK3β a critical amplifier of cellular stress responses and a key player in the molecular cascades that lead to neurodegeneration.
The activity of GSK3β is regulated at multiple levels: through post-translational modifications (phosphorylation, sumoylation, oxidation), subcellular localization, and protein-protein interactions. In neurodegenerative diseases, these regulatory mechanisms become dysregulated, leading to excessive GSK3β activity that contributes to the accumulation of pathological protein aggregates, synaptic dysfunction, and neuronal death. Understanding these regulatory mechanisms has become a major focus for developing disease-modifying therapies for Alzheimer's disease and related disorders.
GSK3β is a proline-directed serine/threonine kinase that phosphorylates over 100 substrates, including:
GSK3β activity is tightly regulated through multiple mechanisms:
Inhibitory phosphorylation: Ser9 phosphorylation by Akt, PKA, PKC, and other kinases inhibits GSK3β activity by blocking the substrate-binding pocket. This phosphorylation is reversed by protein phosphatases including PP1 and PP2A.
Activating phosphorylation: Phosphorylation at Tyr216 in the activation loop is required for full catalytic activity. This phosphorylation can be achieved by autophosphorylation or by kinases such as PYK2 and MEK1.
Subcellular localization: GSK3β localizes to different cellular compartments where it has access to different substrate pools. Nuclear GSK3β phosphorylates transcription factors, while synaptic GSK3β affects synaptic proteins.
Protein interactions: Scaffold proteins such as Frat/GBP and Axin bring GSK3β into complex with specific substrates, increasing the efficiency and specificity of phosphorylation.
GSK3β is a major downstream target of the PI3K/Akt signaling pathway, one of the most important pro-survival pathways in neurons. When growth factors such as BDNF or IGF-1 activate their receptors, PI3K is activated and produces PIP3, which activates Akt. Akt then phosphorylates GSK3β at Ser9, inhibiting its activity. This pathway is crucial for neuronal survival, and its dysfunction contributes to neurodegeneration. In Alzheimer's disease, impaired PI3K/Akt signaling leads to reduced GSK3β inhibition, increased tau phosphorylation, and accelerated neurofibrillary tangle formation.
GSK3β is a central component of the canonical Wnt/β-catenin signaling pathway. In the absence of Wnt signaling, GSK3β (as part of the destruction complex with Axin, APC, and β-catenin) phosphorylates β-catenin, targeting it for ubiquitination and degradation. When Wnt binds to its receptors, the destruction complex is inhibited, β-catenin accumulates and translocates to the nucleus, where it activates TCF/LEF-dependent gene transcription. In neurodegeneration, dysregulated Wnt signaling contributes to cognitive deficits and impaired synaptic plasticity.
GSK3β regulates NF-κB signaling in a complex manner. GSK3β phosphorylates IκBα, promoting its degradation and NF-κB activation in some contexts. However, GSK3β also phosphorylates RelA/p65, which can inhibit its transcriptional activity. The net effect of GSK3β on NF-κB signaling depends on the cellular context and the specific NF-κB target genes involved.
GSK3β interacts with the MAPK/ERK pathway at multiple levels. ERK can phosphorylate and activate GSK3β, while GSK3β can phosphorylate components of the MAPK pathway. This cross-talk is important for neuronal plasticity and survival. In AD, hyperactive GSK3β interacts with dysregulated MAPK signaling to promote tau pathology and synaptic dysfunction.
GSK3β is a major tau kinase implicated in AD pathogenesis[@gong2020]. Hyperactive GSK3β phosphorylates tau at multiple sites (Ser199, Ser202, Thr205, Ser396, Ser404), promoting neurofibrillary tangle formation. GSK3β also contributes to amyloid-β production and synaptic dysfunction through multiple mechanisms: phosphorylating APP and BACE1 to enhance Aβ generation, promoting NMDA receptor internalization and impairing LTP, activating tau kinases that amplify the amyloid response, and contributing to microglial activation and neuroinflammation.
The convergence of GSK3β dysregulation with other AD pathological features creates a feedforward cycle that accelerates disease progression. As tau pathology spreads, more GSK3β becomes associated with neurofibrillary tangles, further increasing local kinase activity. Meanwhile, Aβ oligomers activate several kinases that feed into GSK3β activation, creating a vicious cycle between amyloid and tau pathologies.
In PD, GSK3β promotes α-synuclein phosphorylation at Ser129, enhancing its aggregation[@cataldo2020]. GSK3β also contributes to dopaminergic neuron death through mitochondrial dysfunction and oxidative stress. The kinase phosphorylates and inactivates key mitochondrial proteins, impairs mitophagy, and promotes the activation of cell death pathways. GSK3β activity is elevated in PD models and in patient brains, making it a potential therapeutic target.
GSK3β also interacts with other PD-related proteins including LRRK2, where GSK3β may phosphorylate LRRK2 and modulate its toxic effects, and parkin, where GSK3β can be sequestered into aggregates, reducing its availability for mitophagy regulation.
In HD, GSK3β activity is elevated and contributes to mutant huntingtin toxicity[@bahader2020]. GSK3β phosphorylates huntingtin at multiple sites, enhancing its aggregation and nuclear toxicity. The kinase also contributes to transcriptional dysregulation by phosphorylating transcription factors that are misregulated in HD. Inhibiting GSK3β in HD models reduces mutant huntingtin aggregation and improves behavioral outcomes.
In ALS, GSK3β promotes TDP-43 pathology, a hallmark feature of most ALS cases. GSK3β phosphorylates TDP-43 at multiple sites, promoting its aggregation and mislocalization from the nucleus to the cytoplasm. The kinase also contributes to excitotoxicity by modulating glutamate transporter expression and receptor function.
GSK3β is a well-established target of mood stabilizers used to treat bipolar disorder. Lithium directly inhibits GSK3β by competing with Mg2+ at the active site, while also promoting Ser9 phosphorylation through Akt activation. Valproate similarly inhibits GSK3β through multiple mechanisms. These observations established GSK3β as a key node in mood regulation and motivated research into GSK3β inhibitors as treatments for mood disorders.
Despite decades of research, GSK3β inhibitors have not yet achieved clinical success for neurodegeneration. Key challenges include:
Limited brain penetration: Many early GSK3β inhibitors failed to achieve adequate brain concentrations.
Narrow therapeutic window: Complete GSK3β inhibition causes unacceptable side effects, particularly in peripheral tissues.
Multiple substrate effects: Broad inhibition of all GSK3β substrates leads to complex, sometimes contradictory effects.
Alternative pathway activation: Compensatory mechanisms can undermine the benefits of GSK3β inhibition.
New strategies for targeting GSK3β in neurodegeneration include:
Isoform-selective inhibitors: Developing compounds that preferentially inhibit GSK3β over GSK3α may reduce side effects.
Substrate-directed approaches: Targeting the interaction between GSK3β and specific substrates (such as tau) may provide more specific therapy.
Allosteric modulators: Targeting regulatory sites rather than the active site may provide finer control of kinase activity.
Combination therapy: Combining GSK3β inhibition with other disease-modifying approaches may provide additive benefits.
GSK3β is expressed throughout the brain with highest levels in:
Current models have limitations that complicate translation to human disease. Many models overexpress GSK3β at non-physiological levels, and acute toxin models do not fully replicate the chronic progressive nature of human neurodegeneration.
GSK3β phosphorylates tau at multiple sites that are hyperphosphorylated in AD brain. The kinase prefers primed substrates, meaning tau must first be phosphorylated at a priming site (such as Thr205) for efficient phosphorylation at downstream sites (such as Ser396/404). This priming is often provided by other kinases such as CDK5. The balance between kinase (GSK3β) and phosphatase (PP2A) activities determines tau phosphorylation state, and this balance is shifted toward hyperphosphorylation in AD.
GSK3β regulates synaptic function through phosphorylation of multiple synaptic proteins. At glutamatergic synapses, GSK3β phosphorylates NMDA and AMPA receptor subunits, affecting their trafficking and function. GSK3β also regulates the dynamics of dendritic spines through effects on actin cytoskeletal proteins. These functions explain the early synaptic dysfunction observed in AD and the cognitive deficits that result.
GSK3β modulates gene expression through phosphorylation of transcription factors including CREB, NF-κB, c-Myc, and β-catenin. By regulating these transcription factors, GSK3β affects the expression of genes involved in neuronal survival, synaptic plasticity, and inflammation. Dysregulated GSK3β activity thus has broad effects on the neuronal transcriptome.
GSK3β localizes to mitochondria where it phosphorylates various mitochondrial proteins. In neurodegeneration, excessive GSK3β activity impairs mitochondrial function by affecting electron transport chain complexes, promoting mitochondrial permeability transition, and inhibiting mitophagy. These effects contribute to the bioenergetic deficits and oxidative stress observed in AD, PD, and related disorders.
GSK3β plays a critical role in regulating microglial activation and neuroinflammation, both of which are central features of neurodegenerative diseases. In resting microglia, GSK3β activity is maintained at moderate levels through inhibitory Ser9 phosphorylation. Upon activation by inflammatory stimuli, GSK3β activity is modulated in complex ways that affect the microglial phenotype.
GSK3β regulates the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 through effects on NF-κB and MAPK signaling pathways. Inhibition of GSK3β generally reduces pro-inflammatory cytokine production, while excessive GSK3β activity promotes neuroinflammation. This has led to interest in GSK3β inhibitors as anti-inflammatory agents for neurodegenerative diseases.
The anti-inflammatory effects of GSK3β inhibition may contribute to the therapeutic benefits of mood stabilizers like lithium in neurodegenerative conditions. Additionally, microglial modulation represents a potential indirect pathway through which GSK3β inhibitors could provide neuroprotection beyond direct effects on neurons.
GSK3β is a critical regulator of synaptic plasticity, with complex effects on both LTP and LTD. During LTP induction, GSK3β activity is suppressed through inhibitory Ser9 phosphorylation, allowing for the stable strengthening of synaptic connections. Sustained GSK3β activity during the maintenance phase of LTP can reverse synaptic strengthening, suggesting that balanced GSK3β activity is essential for proper plasticity.
GSK3β also participates in LTD, where it is activated by mGluR signaling and contributes to AMPA receptor internalization. This function is particularly relevant to Alzheimer's disease, where excessive LTD-like processes may contribute to synaptic loss. The bidirectional regulation of plasticity by GSK3β highlights the importance of precise kinase activity regulation.
The role of GSK3β in synaptic plasticity translates to effects on memory formation and consolidation. GSK3β activity must be precisely regulated during memory processes, with both excessive and insufficient activity impairing cognitive function. This delicate balance explains why broad GSK3β inhibition can have limited therapeutic benefit in AD patients.
The following diagram shows the key molecular relationships involving GSK3B Gene - Glycogen Synthase Kinase 3 Beta discovered through SciDEX knowledge graph analysis: